A Phase 1 interventional study of DR10624 for injection and Placebo in Healthy, Obesity, Metabolically, sponsored by Zhejiang Doer Biologics Co., Ltd.. Completed at 1 site in New Zealand. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Zhejiang Doer Biologics Co., Ltd. (part of Huadong Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
DR10624 is an Fc fusion protein tri-agonist with balanced glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR)/ fibroblast growth factor 21 receptor (FGF21R) agonizing activities. The objectives of the planned clinical investigation will be to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single- and multiple-ascending doses of DR10624 via subcutaneous (SubQ) injection in a randomized, placebo-controlled, double-blind study.
This study includes 2 parts( 1 and 2). Part 1 involves a single dose of DR10624 taken as a subcutaneous injection just under the skin. Part 2 involve multiple doses of DR10624 taken as a subcutaneous injection (SC) just under the skin. Each participant will enroll in only one part.
27 studies on the registry are indexed under Obesity, Metabolically Benign; 8 are open to participants now.
This study's enrollment of 153 is above the median of 60 across 17 interventional studies indexed under Obesity, Metabolically Benign.
Browse Obesity, Metabolically Benign studies →Zhejiang Doer Biologics Co., Ltd. is the lead sponsor of 9 studies on the registry; 5 are open to participants now.
First submitted after Zhejiang Doer Biologics Co., Ltd. became part of Huadong Medicine Co., Ltd..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subjects (heterosexually active, of , not pregnant, not trying to become pregnant, and not lactating) are eligible to participate if they agree to total abstinence from heterosexual intercourse or use a highly effective method of listed below, from screening through until at least 30 days after the last dose of the study drug.
Male subjects with female partners of childbearing potential are eligible to participate if they are vasectomized, or agree to total abstinence from heterosexual intercourse, from screening through until at least 30 days after the last study dose, or use of an effective method of birth control listed above, from screening through until at least 30 days after the last study dose. Male subjects must refrain from sperm donation throughout the study and for 30 days after the last study dose.
Additional inclusion criteria for Part 1:
Additional inclusion criteria for Part 2:
Exclusion Criteria:
The subject has history or presence of findings as determined by the investigator at screening and check-in,
- Uncontrolled hypertension (defined as systolic blood pressure (SBP) ≥160 mmHg, and/or diastolic blood pressure (DBP) ≥100 mmHg), angina, bradycardia (if assessed as clinically significant by the investigator), or severe peripheral arterial circulatory disorders.
Additional exclusion criteria for subjects in Part 2:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Escalating doses of DR10624 for injection administered subcutaneously in healthy participants or obese but otherwise healthy participants
Drug: DR10624 for injection
Escalating doses of placebo for injection administered subcutaneously in in healthy participants or obese but otherwise healthy participants
Drug: Placebo
Escalating doses of DR10624 for injection administered subcutaneously in obese adult subjects with moderate hypertriglyceridemia
Drug: DR10624 for injection
Escalating doses of placebo for injection administered subcutaneously in obese adult subjects with moderate hypertriglyceridemia
Drug: Placebo
A SAD part in Chinese healthy adult subjects or overweight or obese adults but otherwise healthy adult subjects.
Drug: DR10624 for injection
A SAD part in Chinese healthy adult subjects or overweight or obese adults but otherwise healthy adult subjects.
Drug: Placebo
administered via subcutaneous injection
administered via subcutaneous injection
Assess the Safety and Tolerability
Area under the serum concentration-time curve (AUC). For Part 1 and Part 3, AUC from time 0 to infinity (AUC0-inf) is presented. For Part 2, AUC over the dosing interval (AUC0-tau) assessed from pre-dose on Day 78 to 168 hours post-dose is presented. Data presented are from baseline through Day 29 (Part 1 and Part 3) and from pre-final dose on Day 78 through Day 106 (Part 2)
Time frame: Baseline through Day 29 (Part 1 & Part 3); Pre-final dose on Day 78 through Day 106 (Part 2)
Area Under the Serum Concentration Versus Time Curve (AUC)
The area under the serum concentration versus time curve from Time 0 to Time t (AUC0-t), which is calculated over the following time frames: baseline through Day 29 for Part 1 and Part 3; for Part 2, from pre-dose of the final dose on Day 78 to post-dose Day 106 (Day 29 after the final dose).
Time frame: baseline through day 29 (part 1and part 3)or day 106 (part 2)
Maximum Observed Serum Concentration (Cmax)
Maximum observed serum concentration (Cmax). For Part 1 and Part 3, data are presented from baseline through Day 29. For Part 2, data after the final dose (administered on Day 78) are presented through Day 106. The time frame for data collection spans the entire study period for each part as indicated.
Time frame: baseline through day 29 (part 1and part 3) or day 106 (part 2)
Time to Reach Maximum Observed Serum Concentration (Tmax)
Maximum observed serum concentration (Cmax). For Part 1 and Part 3, data are presented from baseline through Day 29. For Part 2, data after the final dose (administered on Day 78) are presented through Day 106. The time frame for data collection spans the entire study period for each part as indicated.
Time frame: baseline through day 29 (part 1and part 3) or day 106 (part 2).
Terminal Elimination Half-life (t1/2)
Maximum observed serum concentration (Cmax). For Part 1 and Part 3, data are presented from baseline through Day 29. For Part 2, data after the final dose (administered on Day 78) are presented through Day 106. The time frame for data collection spans the entire study period for each part as indicated.
Time frame: baseline through day 29 (part 1and part 3) or day 106 (part 2).
Apparent Clearance After Extravascular Administration (CL/F)
Maximum observed serum concentration (Cmax). For Part 1 and Part 3, data are presented from baseline through Day 29. For Part 2, data after the final dose (administered on Day 78) are presented through Day 106. The time frame for data collection spans the entire study period for each part as indicated.
Time frame: baseline through day 29 (part 1and part 3) or day 106 (part 2)
Apparent Volume of Distribution During the Terminal Elimination Phase After Extravascular Administration (Vz/F)
Maximum observed serum concentration (Cmax). For Part 1 and Part 3, data are presented from baseline through Day 29. For Part 2, data after the final dose (administered on Day 78) are presented through Day 106. The time frame for data collection spans the entire study period for each part as indicated.
Time frame: baseline through day 29 (part 1and part 3) or day 106 (part 2)
Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf)
Area Under the Plasma Concentration-Time Curve from Time 0 to Infinity (AUC0-inf)
Time frame: baseline through day29(part 1 and part 3 )
Change in Body Weight
the difference in LS Means body weight change from baseline compared with placebo
Time frame: baseline through Day 85(part 2)
Change in Adiponectin
the difference in LS Means adiponectin change from baseline compared with placebo
Time frame: baseline through Day 85
the Difference in LS Means BMI Change From Baseline Compared With Placebo
change in BMI
Time frame: baseline through Day 85(part 2)
the Difference in LS Means Waist Circumference Change From Baseline Compared With Placebo
change in waist circumference
Time frame: baseline through Day 85(part 2)
Change in Fasting Lipid Profile
the difference in LS Means Ratio fasting lipid profile change from baseline compared with placebo
Time frame: baseline through Day 85(part 2)
Change in Fasting Plasma Glucose (FPG)
the difference in LS Means FPG change from baseline compared with placebo
Time frame: baseline through Day 85
Change in C-peptide
the difference in LS Means Ratio of C-peptide change from baseline compared with placebo
Time frame: baseline through Day 85(part 2)
Change in Fasting Insulin
the difference in LS Means Ratio of fasting insulin change from baseline compared with placebo
Time frame: baseline through Day 85(part 2)
Change in Hemoglobin A1C
the difference in LS Means Ratio of Hemoglobin A1C change from baseline compared with placebo
Time frame: baseline through Day 85(part 2)
Change in Glucagon
the difference in LS Means Ratio fasting glucagon change from baseline compared with placebo
Time frame: baseline through Day 85
Change in Homeostatic Model Assessment Index of Insulin Resistance (HOMA-IR) and Homeostatic Model Assessment Index of Beta-cell Function (HOMA-B)
The difference in LS Means Ratio HOMA-IR and HOMA-B change from baseline compared with placebo. HOMA-IR: (Fasting Insulin \[μU/mL\] × Fasting Glucose \[mmol/L\]) / 22.5; HOMA-β: (20 × Fasting Insulin \[μU/mL\]) / (Fasting Glucose \[mmol/L\] - 3.5). For HOMA-IR: lower values indicate improved insulin sensitivity (less insulin resistance), representing a better outcome. For HOMA-B: higher values indicate enhanced pancreatic beta-cell function, representing a better outcome.
Time frame: baseline through Day 85
Percent Change From Baseline in Hepatic Fat Fraction Measured by MRI-PDFF in Part 2
percentage change from baseline in hepatic fat fraction measured by MRI-PDFF in part 2. Percent change was calculated as \[(post-baseline value - baseline value) / baseline value\] × 100.
Time frame: Baseline (screening) and Day 85 to Day 99 in Part 2
Positive Rate of ADA
overall positive rate of ADA at EOS
Time frame: from baseline to the end of the study, up to Day29s (part1, part3), up to Day106s (part2)
Continuous Glucose Monitoring Outcome
Individual results of CGM endpoints and results are presented by subject in the listing contained in the CSR attachment.
Time frame: from baseline to D79(part 2)
Change in Fibrosis 4 Index
Change in Fibrosis 4 Index from baseline. Fibrosis 4 Index (FIB-4) is a continuous calculated score for liver fibrosis staging, derived from the formula: FIB-4 = (age \[years\] × AST \[U/L\]) / (platelet count \[10\^9/L\] × √ALT \[U/L\]), which can be used to identify patients with a low probability of advanced fibrosis. The theoretical minimum value is 0, and there is no predefined maximum value (the score is open-ended). Lower values indicate a lower probability of advanced liver fibrosis, representing a better outcome. For clinical interpretation, commonly used cutoff values are as follows: FIB-4 \< 1.3: low probability of advanced liver fibrosis (better outcome); 1.3 ≤ FIB-4 \< 3.25: indeterminate fibrosis stage; FIB-4 ≥ 3.25: high probability of advanced liver fibrosis (worse outcome).
Time frame: from baseline to D85(part 2)
Change in Non-Alcoholic Fatty Liver Disease Fibrosis Score
The Non-Alcoholic Fatty Liver Disease Fibrosis Score (NFS) is a derived non-invasive fibrosis score calculated as -1.675 + 0.037 × age (year) + 0.094 × BMI (kg/m\^2) + 1.13 × impaired fasting glucose or diabetes (yes=1, no=0) + 0.99 × AST/ALT ratio - 0.013 × platelet count (×10\^9/L) - 0.66 × albumin (g/dL). This score does not have a fixed theoretical minimum or maximum; higher values indicate greater likelihood of advanced fibrosis
Time frame: from baseline to D85 (part 2)
Change in Alanine Aminotransferase
change in Alanine Aminotransferase from baseline
Time frame: from baseline to D85 (part 2)
Change in Aspartate Aminotransferase
change in Aspartate Aminotransferase from baseline
Time frame: from baseline to D85 (part 2)
Change in Partial Area Glucose Levels Versus Time Curve From Time 0 to 4 Hours (△AUC0-4h)
change in Partial area glucose levels versus time curve from time 0 to 4 hours (△AUC0-4h) from baseline
Time frame: from 0 to 4 hours on D79
Change in Partial Area Insulin Levels Versus Time Curve From Time 0 to 4 Hours (△AUC0-4h)
change in Partial area insulin levels versus time curve from time 0 to 4 hours (△AUC0-4h) from baseline
Time frame: from 0 to 4 hours on D79
Change in Partial Area C-peptide Levels Versus Time Curve From Time 0 to 4 Hours (△AUC0-4h)
change in Partial area C-peptide levels versus time curve from time 0 to 4 hours (△AUC0-4h) from baseline
Time frame: from 0 to 4 hours on D79
Change in Partial Area Glucagon Levels Versus Time Curve From Time 0 to 4 Hours (△AUC0-4h)
change in Partial area glucagon levels versus time curve from time 0 to 4 hours (△AUC0-4h) from baseline
Time frame: from 0 to 4 hours on D79
Change Percentage of Time Spent of Glucose in Target Range 3.9 to 10 mmol/L (TIR), Time Above Target Range (TAR), Time Below Target Range (TBR), 24-hour Mean Glucose, and Glucose Variability
statistical analysis of TIR, TAR, TBR, 24-hour mean glucose and glucose variability was not performed due to small sample size
Time frame: baseline through Day 85(part 2)
This was a randomised, double-blinded, parallel-design, placebo-controlled, multi-national, and multi-centre study with different DR10624 doses (Single-Ascending and Multiple-Ascending doses ranging from 1.5 mg/week to 120 mg/week) in patients with healthy or overweight to obese, and obese with modest hypertriglyceridemia.
| Milestone | Single-ascending Dose:Part1:DR10624 0.5mg | Single-ascending Dose:Part1:DR10624 1.5mg | Single-ascending Dose:Part1:DR10624 4.5mg | Single-ascending Dose:Part1:DR10624 12.5mg | Single-ascending Dose:Part1:DR10624 25mg | Single-ascending Dose:Part1:DR10624 50mg | Single-ascending Dose:Part1:DR10624 65mg | Single-ascending Dose:Part1:DR10624 90mg | Single-ascending Dose:Part1:DR10624 120mg | Single-ascending Dose:Part1:Placebo | Multiple-ascending Dose:Part2:DR10624 12.5mg | Multiple-ascending Dose:Part2:DR10624 25mg | Multiple-ascending Dose:Part2:DR10624 50mg | Multiple-ascending Dose:Part2:DR10624 75mg | Multiple-ascending Dose:Part2:Placebo | Single-ascending Dose:Part3:DR10624 65mg | Single-ascending Dose:Part3:DR10624 90mg | Single-ascending Dose:Part3:DR10624 25mg | Single-ascending Dose:Part3:Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 16 | 10 | 10 | 11 | 10 | 8 | 10 | 10 | 10 | 6 |
| Completed | 4 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 16 | 9 | 9 | 8 | 8 | 7 | 10 | 10 | 10 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 2 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other reason | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Area under the serum concentration-time curve (AUC). For Part 1 and Part 3, AUC from time 0 to infinity (AUC0-inf) is presented. For Part 2, AUC over the dosing interval (AUC0-tau) assessed from pre-dose on Day 78 to 168 hours post-dose is presented. Data presented are from baseline through Day 29 (Part 1 and Part 3) and from pre-final dose on Day 78 through Day 106 (Part 2)
| participants | DR10624 0.5mg Part1 | DR10624 1.5mg part1 | DR10624 4.5mg part1 | DR10624 12.5mg part1 | DR10624 25mg part1 | DR10624 50mg part1 | DR10624 65mg part1 | DR10624 90mg part1 | DR10624 120mg part1 | Single-ascending Dose:Part1:Placebo | DR10624 12.5mg Part2 | DR10624 25mg part2 | DR10624 50mg part2 | DR10624 75mg part2 | Multiple-ascending Dose:Part2:Placebo | DR10624 25mg Part 3 | DR10624 65mg part3 | DR10624 90mg part3 | Single Ascending Dose :Part 3:Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any TEAE — Any TEAE | 4 | 5 | 4 | 6 | 5 | 6 | 6 | 5 | 5 | 12 | 10 | 10 | 11 | 10 | 7 | 7 | 6 | 7 | 5 |
| Any Treatment-Related TEAE — Any TEAE | 0 | 1 | 2 | 3 | 3 | 6 | 6 | 4 | 4 | 4 | 6 | 8 | 11 | 10 | 5 | 5 | 3 | 7 | 0 |
The area under the serum concentration versus time curve from Time 0 to Time t (AUC0-t), which is calculated over the following time frames: baseline through Day 29 for Part 1 and Part 3; for Part 2, from pre-dose of the final dose on Day 78 to post-dose Day 106 (Day 29 after the final dose).
| h*ng/mL | DR10624 0.5mg Part 1 | DR10624 1.5 mg Part 1 | DR10624 4.5 mg Part 1 | DR10624 12.5mg Part 1 | DR10624 25mg Part 1 | DR10624 50mg Part 1 | DR10624 65mg Part 1 | DR10624 90mg Part 1 | DR10624 120mg Part 1 | DR10624 12.5mg Part 2 | DR10624 25mg Part 2 | DR10624 50mg Part 2 | DR10624 75mg Part 2 | DR10624 25mg Part 3 | DR10624 65mg Part 3 | DR10624 90mg Part 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Serum Concentration Versus Time Curve (AUC) | 5000 ± 59.2 | 21800 ± 19.4 | 64200 ± 25.4 | 266000 ± 35.4 | 457000 ± 24.7 | 1360000 ± 32.7 | 789000 ± 23.3 | 1020000 ± 29.8 | 1360000 ± 39.2 | 223000 ± 43.9 | 602000 ± 38.2 | 1000000 ± 19.3 | 1980000 ± 33.5 | 245000 ± 49.3 | 668000 ± 51.3 | 976000 ± 30.2 |
Maximum observed serum concentration (Cmax). For Part 1 and Part 3, data are presented from baseline through Day 29. For Part 2, data after the final dose (administered on Day 78) are presented through Day 106. The time frame for data collection spans the entire study period for each part as indicated.
| ng/mL | DR10624 0.5mg Part 1 | DR10624 1.5mg part1 | DR10624 4.5mg Part 1 | DR10624 12.5mg part1 | DR10624 25mg part1 | DR10624 50mg part1 | DR10624 65mg part1 | DR10624 90mg part1 | DR10624 120mg part1 | DR10624 12.5mg part2 | DR10624 25mg part2 | DR10624 50mg part2 | DR10624 75mg part2 | DR10624 25mg part3 | DR10624 65mg part3 | DR10624 90mg part3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Maximum Observed Serum Concentration (Cmax) | 33.0 ± 53.8 | 110 ± 35.5 | 307 ± 46.9 | 1210 ± 53.8 | 2010 ± 29.8 | 5950 ± 43.4 | 3420 ± 35.2 | 3870 ± 32.4 | 7000 ± 54.7 | 987 ± 37.5 | 2610 ± 42.1 | 4540 ± 22.6 | 7960 ± 35.2 | 1130 ± 68.2 | 2880 ± 72.4 | 4300 ± 39.9 |
Maximum observed serum concentration (Cmax). For Part 1 and Part 3, data are presented from baseline through Day 29. For Part 2, data after the final dose (administered on Day 78) are presented through Day 106. The time frame for data collection spans the entire study period for each part as indicated.
| h | DR10624 0.5mg part1 | DR10624 1.5mg part1 | DR10624 4.5mg part1 | DR10624 12.5mg part1 | DR10624 25mg part1 | DR10624 50mg part1 | DR10624 65mg part1 | DR10624 90mg part1 | DR10624 120mg part1 | DR10624 12.5mg Part 2 | DR10624 25mg part2 | DR10624 50mg part2 | DR10624 75mg part2 | DR10624 25mg part3 | DR10624 65mg part3 | DR10624 90mg part3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Time to Reach Maximum Observed Serum Concentration (Tmax) | 72.00 (48.03 to 72.00) | 48.00 (48.00 to 120.00) | 72.00 (48.00 to 96.00) | 72.00 (48.00 to 120.00) | 84.00 (48.00 to 96.00) | 72.00 (48.05 to 144.13) | 96.09 (48.00 to 120.00) | 96.00 (72.00 to 96.02) | 60.03 (24.02 to 168.00) | 48.06 (45.98 to 96.00) | 48.03 (46.13 to 96.47) | 95.98 (47.27 to 119.17) | 69.48 (47.87 to 96.10) | 72.02 (47.98 to 119.98) | 83.87 (47.78 to 240.03) | 72.00 (47.75 to 95.75) |
Maximum observed serum concentration (Cmax). For Part 1 and Part 3, data are presented from baseline through Day 29. For Part 2, data after the final dose (administered on Day 78) are presented through Day 106. The time frame for data collection spans the entire study period for each part as indicated.
| h | DR10624 0.5mg Part 1 | DR10624 1.5mg part1 | DR10624 4.5mg part1 | DR10624 12.5mg part1 | DR10624 25mg part1 | DR10624 50mg part1 | DR10624 65mg part1 | DR10624 90mg part1 | DR10624 120mg part1 | DR10624 12.5mg Part 2 | DR10624 25mg part2 | DR10624 50mg part2 | DR10624 75mg part2 | DR10624 25mg part3 | DR10624 65mg part3 | DR10624 90mg part3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Terminal Elimination Half-life (t1/2) | 77.9 ± 33.3 | 77.3 ± 27.2 | 71.0 ± 17.0 | 81.0 ± 10.2 | 92.6 ± 11.8 | 89.5 ± 6.5 | 91.4 ± 10.8 | 86.0 ± 21.2 | 107 ± 14.5 | 94.1 ± 20.2 | 101 ± 11.7 | 102 ± 13.7 | 106 ± 11.7 | 80.1 ± 20.9 | 80.6 ± 14.4 | 94.7 ± 20.8 |
Maximum observed serum concentration (Cmax). For Part 1 and Part 3, data are presented from baseline through Day 29. For Part 2, data after the final dose (administered on Day 78) are presented through Day 106. The time frame for data collection spans the entire study period for each part as indicated.
| L/h | DR10624 0.5mg part1 | DR10624 1.5mg part1 | DR10624 4.5mg part1 | DR10624 12.5mg part1 | DR10624 25mg part1 | DR10624 50mg part1 | DR10624 65mg part1 | DR10624 90mg part1 | DR10624 120mg part1 | DR10624 12.5mg Part 2 | DR10624 25mg part2 | DR10624 50mg part2 | DR10624 75mg part2 | DR10624 25mg part3 | DR10624 65mg part3 | DR10624 90mg part3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apparent Clearance After Extravascular Administration (CL/F) | 0.0586 ± 21.8 | 0.0655 ± 18.5 | 0.0689 ± 25.0 | 0.0466 ± 34.8 | 0.0542 ± 24.3 | 0.0364 ± 32.7 | 0.0816 ± 23.3 | 0.0875 ± 29.7 | 0.0867 ± 38.5 | 0.0928 ± 36.4 | 0.0715 ± 35.7 | 0.0843 ± 23.3 | 0.0687 ± 29.4 | 0.101 ± 48.5 | 0.0965 ± 50.8 | 0.0910 ± 30.0 |
Maximum observed serum concentration (Cmax). For Part 1 and Part 3, data are presented from baseline through Day 29. For Part 2, data after the final dose (administered on Day 78) are presented through Day 106. The time frame for data collection spans the entire study period for each part as indicated.
| L | DR10624 0.5mg Part 1 | DR10624 1.5mg part1 | DR10624 4.5mg part1 | DR10624 12.5mg part1 | DR10624 25mg part1 | DR10624 50mg part1 | DR10624 65mg part1 | DR10624 90mg part1 | DR10624 120mg part1 | DR10624 12.5mg Part 2 | DR10624 25mg part2 | DR10624 50mg part2 | DR10624 75mg part2 | DR10624 25mg part3 | DR10624 65mg part3 | DR10624 90mg part3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apparent Volume of Distribution During the Terminal Elimination Phase After Extravascular Administration (Vz/F) | 5.53 ± 54.7 | 7.30 ± 35.8 | 7.06 ± 41.5 | 5.45 ± 42.9 | 7.24 ± 29.4 | 4.71 ± 33.0 | 10.8 ± 24.3 | 10.8 ± 39.7 | 13.4 ± 50.5 | 12.6 ± 30.9 | 10.4 ± 43.5 | 12.4 ± 33.1 | 10.6 ± 30.6 | 11.7 ± 71.8 | 11.2 ± 56.5 | 12.4 ± 38.3 |
Area Under the Plasma Concentration-Time Curve from Time 0 to Infinity (AUC0-inf)
| h*ng/mL | DR10624 0.5mg Part 1 | DR10624 1.5mg part1 | DR10624 4.5mg Part 1 | DR10624 12.5mg part1 | DR10624 25mg part1 | DR10624 50mg part1 | DR10624 65mg part1 | DR10624 90mg part1 | DR10624 120mg part1 | DR10624 25mg part3 | DR10624 65mg part3 | DR10624 90mg part3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) | 8540 ± 12.8 | 22900 ± 18.5 | 65300 ± 25 | 268000 ± 34.8 | 461000 ± 24.3 | 1370000 ± 32.7 | 797000 ± 23.2 | 1030000 ± 29.7 | 1380000 ± 38.5 | 247000 ± 48.5 | 247000 ± 50.8 | 989000 ± 30 |
the difference in LS Means body weight change from baseline compared with placebo
| kg | DR10624 12.5mg part2 | DR10624 25mg Part 2 | DR10624 50mg Part 2 | DR10624 75mg Part 2 |
|---|---|---|---|---|
| Change in Body Weight | 2.594 (-2.279 to 7.466) | 0.603 (-4.272 to 5.477) | -2.079 (-7.036 to 2.878) | -1.279 (-6.230 to 3.673) |
the difference in LS Means adiponectin change from baseline compared with placebo
| mg/L | DR10624 12.5mg Part 2 | DR10624 25mg Part 2 | DR10624 50mg Part 2 | DR10624 75mg Part 2 |
|---|---|---|---|---|
| Change in Adiponectin | -0.490 (-4.747 to 3.768) | 1.994 (-2.264 to 6.251) | 3.986 (-0.379 to 8.351) | 3.031 (-1.322 to 7.383) |
change in BMI
| kg/m2 | DR10624 12.5mg Part 2 | DR10624 25mg Part 2 | DR10624 50mg Part 2 | DR10624 75mg Part 2 |
|---|---|---|---|---|
| the Difference in LS Means BMI Change From Baseline Compared With Placebo | 0.839 (-0.745 to 2.423) | 0.224 (-1.360 to 1.808) | -0.873 (-2.486 to 0.740) | -0.607 (-2.216 to 1.002) |
change in waist circumference
| cm | DR10624 12.5mg Part 2 | DR10624 25mg Part 2 | DR10624 50mg Part 2 | DR10624 75mg Part 2 |
|---|---|---|---|---|
| the Difference in LS Means Waist Circumference Change From Baseline Compared With Placebo | 3.544 (-3.085 to 10.173) | 4.436 (-2.198 to 11.070) | 1.856 (-4.867 to 8.579) | -0.503 (-7.229 to 6.222) |
the difference in LS Means Ratio fasting lipid profile change from baseline compared with placebo
| mmol/L | DR10624 12.5mg Cholesterol | DR10624 25 mg Cholesterol | DR10624 50 mg Cholesterol | DR10624 75mg Cholesterol | DR10624 12.5 mg LDL Cholesterol | DR10624 25 mg LDL Cholesterol | DR10624 50 mg LDL Cholesterol | DR10624 75mg LDL Cholesterol | DR10624 12.5 mg HDL Cholesterol | DR10624 25 mg HDL Cholesterol | DR10624 50 mg HDL Cholesterol | DR10624 75mg HDL Cholesterol | DR10624 12.5 mg Non-HDL Cholesterol | DR10624 25 mg Non-HDL Cholesterol | DR10624 50 mg Non-HDL Cholesterol | DR10624 75mg Non-HDL Cholesterol | DR10624 12.5 mg Lipoprotein-a | DR10624 25 mg Lipoprotein-a | DR10624 50 mg Lipoprotein-a | DR10624 75mg Lipoprotein-a | DR10624 12.5 mg VLDL Cholesterol | DR10624 25 mg VLDL Cholesterol | DR10624 50 mg VLDL Cholesterol | DR10624 75mg VLDL Cholesterol | DR10624 12.5 mg Triglycerides | DR10624 25 mg Triglycerides | DR10624 50 mg Triglycerides | DR10624 75mg Triglycerides | DR10624 12.5 mg Free Fatty Acid | DR10624 25 mg Free Fatty Acid | DR10624 50 mg Free Fatty Acid | DR10624 75mg Free Fatty Acid |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change in Fasting Lipid Profile | 0.905 (0.817 to 1.002) | 0.932 (0.841 to 1.032) | 0.814 (0.732 to 0.905) | 0.850 (0.767 to 0.943) | 0.874 (0.732 to 1.044) | 1.017 (0.852 to 1.215) | 0.883 (0.735 to 1.061) | 0.928 (0.775 to 1.111) | 1.032 (0.895 to 1.190) | 1.025 (0.888 to 1.183) | 0.957 (0.828 to 1.105) | 0.974 (0.842 to 1.125) | 0.860 (0.760 to 0.973) | 0.899 (0.795 to 1.017) | 0.763 (0.671 to 0.867) | 0.817 (0.721 to 0.926) | 0.970 (0.617 to 1.526) | 1.116 (0.709 to 1.755) | 1.619 (1.023 to 2.564) | 1.991 (1.259 to 3.149) | 0.642 (0.393 to 1.047) | 0.440 (0.270 to 0.719) | 0.318 (0.193 to 0.525) | 0.300 (0.183 to 0.492) | 0.691 (0.486 to 0.983) | 0.460 (0.324 to 0.654) | 0.345 (0.240 to 0.495) | 0.393 (0.275 to 0.562) | 1.036 (0.653 to 1.644) | 0.911 (0.574 to 1.446) | 1.217 (0.764 to 1.940) | 0.953 (0.591 to 1.534) |
the difference in LS Means FPG change from baseline compared with placebo
| mmol/L | DR10624 12.5mg | DR10624 25mg | DR10624 50mg | DR10624 75mg |
|---|---|---|---|---|
| Change in Fasting Plasma Glucose (FPG) | -0.023 (-0.873 to 0.827) | 0.305 (-0.553 to 1.164) | -0.701 (-1.556 to 0.155) | -0.302 (-0.879 to 0.815) |
the difference in LS Means Ratio of C-peptide change from baseline compared with placebo
| pmol/L | DR10624 12.5mg Part 2 | DR10624 25mg Part 2 | DR10624 50mg Part 2 | DR10624 75mg Part 2 |
|---|---|---|---|---|
| Change in C-peptide | 0.762 (0.534 to 1.089) | 0.850 (0.597 to 1.209) | 0.628 (0.438 to 0.899) | 0.676 (0.472 to 0.969) |
the difference in LS Means Ratio of fasting insulin change from baseline compared with placebo
| pmol/L | DR10624 12.5mg | DR10624 25mg | DR10624 50mg | DR10624 75mg |
|---|---|---|---|---|
| Change in Fasting Insulin | 0.520 (0.359 to 0.752) | 0.636 (0.439 to 0.920) | 0.480 (0.329 to 0.700) | 0.589 (0.404 to 0.858) |
the difference in LS Means Ratio of Hemoglobin A1C change from baseline compared with placebo
| mmol/mol | DR10624 12.5mg Part 2 | DR10624 25mg Part 2 | DR10624 50mg Part 2 | DR10624 75mg Part 2 |
|---|---|---|---|---|
| Change in Hemoglobin A1C | 1.012 (0.948 to 1.080) | 0.998 (0.936 to 1.064) | 0.989 (0.926 to 1.055) | 1.013 (0.949 to 1.080) |
the difference in LS Means Ratio fasting glucagon change from baseline compared with placebo
| ng/L | DR10624 12.5mg Part 2 | DR10624 25mg Part 2 | DR10624 50mg Part 2 | DR10624 75mg Part 2 |
|---|---|---|---|---|
| Change in Glucagon | 0.655 (0.194 to 2.206) | 0.238 (0.072 to 0.786) | 0.110 (0.033 to 0.372) | 0.080 (0.024 to 0.264) |
The difference in LS Means Ratio HOMA-IR and HOMA-B change from baseline compared with placebo. HOMA-IR: (Fasting Insulin \[μU/mL\] × Fasting Glucose \[mmol/L\]) / 22.5; HOMA-β: (20 × Fasting Insulin \[μU/mL\]) / (Fasting Glucose \[mmol/L\] - 3.5). For HOMA-IR: lower values indicate improved insulin sensitivity (less insulin resistance), representing a better outcome. For HOMA-B: higher values indicate enhanced pancreatic beta-cell function, representing a better outcome.
| index | DR10624 12.5 mg part2 HOMA-IR | DR10624 25 mg part2 HOMA-IR | DR10624 50 mg part2 HOMA-IR | DR10624 75mg part2 HOMA-IR | DR10624 12.5 mg part2 HOMA-B | DR10624 25 mg part2 HOMA-B | DR10624 50 mg part2 HOMA-B | DR10624 75mg part2 HOMA-B |
|---|---|---|---|---|---|---|---|---|
| Change in Homeostatic Model Assessment Index of Insulin Resistance (HOMA-IR) and Homeostatic Model Assessment Index of Beta-cell Function (HOMA-B) | 0.510 (0.326 to 0.797) | 0.660 (0.421 to 1.034) | 0.420 (0.267 to 0.662) | 0.579 (0.368 to 0.912) | 0.540 (0.286 to 1.020) | 0.504 (0.265 to 0.957) | 0.830 (0.433 to 1.591) | 0.612 (0.321 to 1.168) |
percentage change from baseline in hepatic fat fraction measured by MRI-PDFF in part 2. Percent change was calculated as \[(post-baseline value - baseline value) / baseline value\] × 100.
| percent change of MRI-PDFF | DR10624 12.5mg part2 | DR10624 25mg part2 | DR10624 50mg part2 | DR10624 75mg part2 | Placebo part2 |
|---|---|---|---|---|---|
| Percent Change From Baseline in Hepatic Fat Fraction Measured by MRI-PDFF in Part 2 | -51.88 ± 32.353 | -77.78 ± 14.473 | -78.95 ± 12.870 | -75.76 ± 22.654 | -26.27 ± 17.994 |
overall positive rate of ADA at EOS
| Participants | DR10624 0.5mg Part 1 | DR10624 1.5mg part1 | DR10624 4.5mg part1 | DR10624 12.5mg part1 | DR10624 25mg part1 | DR10624 50mg part1 | DR10624 65mg part1 | DR10624 90mg part1 | DR10624 120mg part1 | DR10624 12.5mg Part 2 | DR10624 25mg part2 | DR10624 50mg part2 | DR10624 75mg part2 | DR10624 25mg part3 | DR10624 65mg part3 | DR10624 90mg part3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Positive Rate of ADA | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Individual results of CGM endpoints and results are presented by subject in the listing contained in the CSR attachment.
Results for this outcome have not been posted.
Change in Fibrosis 4 Index from baseline. Fibrosis 4 Index (FIB-4) is a continuous calculated score for liver fibrosis staging, derived from the formula: FIB-4 = (age \[years\] × AST \[U/L\]) / (platelet count \[10\^9/L\] × √ALT \[U/L\]), which can be used to identify patients with a low probability of advanced fibrosis. The theoretical minimum value is 0, and there is no predefined maximum value (the score is open-ended). Lower values indicate a lower probability of advanced liver fibrosis, representing a better outcome. For clinical interpretation, commonly used cutoff values are as follows: FIB-4 \< 1.3: low probability of advanced liver fibrosis (better outcome); 1.3 ≤ FIB-4 \< 3.25: indeterminate fibrosis stage; FIB-4 ≥ 3.25: high probability of advanced liver fibrosis (worse outcome).
| scores on a scale | DR10624 12.5 mg part2 | DR10624 25 mg part2 | DR10624 50 mg part2 | DR10624 75mg part2 | Placebo part2 |
|---|---|---|---|---|---|
| Change in Fibrosis 4 Index | -0.09 ± 0.125 | -0.14 ± 0.224 | -0.06 ± 0.169 | -0.26 ± 0.437 | -0.14 ± 0.098 |
The Non-Alcoholic Fatty Liver Disease Fibrosis Score (NFS) is a derived non-invasive fibrosis score calculated as -1.675 + 0.037 × age (year) + 0.094 × BMI (kg/m\^2) + 1.13 × impaired fasting glucose or diabetes (yes=1, no=0) + 0.99 × AST/ALT ratio - 0.013 × platelet count (×10\^9/L) - 0.66 × albumin (g/dL). This score does not have a fixed theoretical minimum or maximum; higher values indicate greater likelihood of advanced fibrosis
| units on a scale | DR10624 12.5 mg part2 | DR10624 25 mg part2 | DR10624 50 mg part2 | DR10624 75mg part2 | Placebo part2 |
|---|---|---|---|---|---|
| Change in Non-Alcoholic Fatty Liver Disease Fibrosis Score | 0.14 ± 0.226 | -0.13 ± 0.563 | 0.31 ± 0.728 | 0.10 ± 0.330 | -0.34 ± 0.619 |
change in Alanine Aminotransferase from baseline
| IU/L | DR10624 12.5 mg part2 | DR10624 25 mg part2 | DR10624 50 mg part2 | DR10624 75mg part2 | Placebo part2 |
|---|---|---|---|---|---|
| Change in Alanine Aminotransferase | -5.6 ± 10.50 | 1.3 ± 12.04 | -0.8 ± 6.86 | -8.6 ± 22.32 | -5.9 ± 9.58 |
change in Aspartate Aminotransferase from baseline
| IU/L | DR10624 12.5 mg part2 | DR10624 25 mg part2 | DR10624 50 mg part2 | DR10624 75mg part2 | Placebo part2 |
|---|---|---|---|---|---|
| Change in Aspartate Aminotransferase | -4.89 ± 6.451 | -5.61 ± 7.889 | -4.25 ± 5.898 | -11.25 ± 20.289 | -4.00 ± 6.083 |
change in Partial area glucose levels versus time curve from time 0 to 4 hours (△AUC0-4h) from baseline
| h*mmol/L | DR10624 12.5 mg part2 | DR10624 25 mg part2 | DR10624 50 mg part2 | DR10624 75mg part2 | Placebo part2 |
|---|---|---|---|---|---|
| Change in Partial Area Glucose Levels Versus Time Curve From Time 0 to 4 Hours (△AUC0-4h) | -2.372 ± 3.4613 | 0.670 ± 1.6414 | -0.614 ± 1.5157 | 1.076 ± 2.3229 | 0.502 ± 1.4597 |
change in Partial area insulin levels versus time curve from time 0 to 4 hours (△AUC0-4h) from baseline
| h*pmol/L | DR10624 12.5 mg part2 | DR10624 25 mg part2 | DR10624 50 mg part2 | DR10624 75mg part2 | Placebo part2 |
|---|---|---|---|---|---|
| Change in Partial Area Insulin Levels Versus Time Curve From Time 0 to 4 Hours (△AUC0-4h) | -543.332 ± 741.3500 | -213.593 ± 907.3172 | -925.121 ± 724.0457 | -245.586 ± 676.1720 | 349.545 ± 810.0063 |
change in Partial area C-peptide levels versus time curve from time 0 to 4 hours (△AUC0-4h) from baseline
| h*pmol/L | DR10624 12.5 mg part2 | DR10624 25 mg part2 | DR10624 50 mg part2 | DR10624 75mg part2 | Placebo part2 |
|---|---|---|---|---|---|
| Change in Partial Area C-peptide Levels Versus Time Curve From Time 0 to 4 Hours (△AUC0-4h) | -1607.643 ± 2296.2616 | 175.979 ± 2712.0876 | -1526.766 ± 1958.0598 | -934.313 ± 1252.3779 | 277.850 ± 1407.1687 |
change in Partial area glucagon levels versus time curve from time 0 to 4 hours (△AUC0-4h) from baseline
| h*ng/mL | DR10624 12.5 mg part2 | DR10624 25 mg part2 | DR10624 50 mg part2 | DR10624 75mg part2 | Placebo part2 |
|---|---|---|---|---|---|
| Change in Partial Area Glucagon Levels Versus Time Curve From Time 0 to 4 Hours (△AUC0-4h) | 13.768 ± 25.2027 | -16.809 ± 19.2574 | -15.879 ± 26.3393 | -67.753 ± 81.4642 | -21.713 ± 54.4851 |
statistical analysis of TIR, TAR, TBR, 24-hour mean glucose and glucose variability was not performed due to small sample size
Results for this outcome have not been posted.
Collected over from enrollment until end of follow-up, part1 up to 29 days, part2 up to 106 days, part3 up to 29 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Single-ascending Dose:Part1:DR10624 0.5mg | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Single-ascending Dose:Part1:DR10624 1.5mg | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Single-ascending Dose:Part1:DR10624 4.5mg | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Single-ascending Dose:Part1:DR10624 12.5mg | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Single-ascending Dose:Part1:DR10624 25mg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Single-ascending Dose:Part1:DR10624 50mg | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Single-ascending Dose:Part1:DR10624 65mg | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Single-ascending Dose:Part1:DR10624 90mg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Single-ascending Dose:Part1:DR10624 120mg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Single-ascending Dose:Part1:Placebo | 0/16 (0%) | 1/16 (6.3%) | 1/16 (6.3%) |
| Multiple-ascending Dose:Part2:DR10624 12.5mg | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Multiple-ascending Dose:Part2:DR10624 25mg | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Multiple-ascending Dose:Part2:DR10624 50mg | 0/11 (0%) | 0/11 (0%) | 11/11 (100%) |
| Multiple-ascending Dose:Part2:DR10624 75mg | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Multiple-ascending Dose:Part2:Placebo | 0/8 (0%) | 0/8 (0%) | 6/8 (75%) |
| Single-ascending Dose:Part 3:DR10624 25mg | 0/10 (0%) | 0/10 (0%) | 3/10 (30%) |
| Single-ascending Dose:Part 3:DR10624 65mg | 0/10 (0%) | 0/10 (0%) | 6/10 (60%) |
| Single-ascending Dose:Part 3:DR10624 90mg | 0/10 (0%) | 0/10 (0%) | 7/10 (70%) |
| Single-ascending Dose:Part3:Placebo | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Event | Single-ascending Dose:Part1:DR10624 0.5mg | Single-ascending Dose:Part1:DR10624 1.5mg | Single-ascending Dose:Part1:DR10624 4.5mg | Single-ascending Dose:Part1:DR10624 12.5mg | Single-ascending Dose:Part1:DR10624 25mg | Single-ascending Dose:Part1:DR10624 50mg | Single-ascending Dose:Part1:DR10624 65mg | Single-ascending Dose:Part1:DR10624 90mg | Single-ascending Dose:Part1:DR10624 120mg | Single-ascending Dose:Part1:Placebo | Multiple-ascending Dose:Part2:DR10624 12.5mg | Multiple-ascending Dose:Part2:DR10624 25mg | Multiple-ascending Dose:Part2:DR10624 50mg | Multiple-ascending Dose:Part2:DR10624 75mg | Multiple-ascending Dose:Part2:Placebo | Single-ascending Dose:Part 3:DR10624 25mg | Single-ascending Dose:Part 3:DR10624 65mg | Single-ascending Dose:Part 3:DR10624 90mg | Single-ascending Dose:Part3:Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| intentional overdoseInfections and infestations | 0/4 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/16 | 0/10 | 0/10 | 0/11 | 0/10 | 0/8 | 0/10 | 0/10 | 0/10 | 0/6 |
| Event | Single-ascending Dose:Part1:DR10624 0.5mg | Single-ascending Dose:Part1:DR10624 1.5mg | Single-ascending Dose:Part1:DR10624 4.5mg | Single-ascending Dose:Part1:DR10624 12.5mg | Single-ascending Dose:Part1:DR10624 25mg | Single-ascending Dose:Part1:DR10624 50mg | Single-ascending Dose:Part1:DR10624 65mg | Single-ascending Dose:Part1:DR10624 90mg | Single-ascending Dose:Part1:DR10624 120mg | Single-ascending Dose:Part1:Placebo | Multiple-ascending Dose:Part2:DR10624 12.5mg | Multiple-ascending Dose:Part2:DR10624 25mg | Multiple-ascending Dose:Part2:DR10624 50mg | Multiple-ascending Dose:Part2:DR10624 75mg | Multiple-ascending Dose:Part2:Placebo | Single-ascending Dose:Part 3:DR10624 25mg | Single-ascending Dose:Part 3:DR10624 65mg | Single-ascending Dose:Part 3:DR10624 90mg | Single-ascending Dose:Part3:Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/4 | 0/6 | 0/6 | 1/6 | 2/6 | 4/6 | 3/6 | 4/6 | 4/6 | 0/16 | 3/10 | 2/10 | 11/11 | 9/10 | 2/8 | 0/10 | 1/10 | 6/10 | 0/6 |
| VomitingGastrointestinal disorders | 0/4 | 0/6 | 0/6 | 1/6 | 0/6 | 2/6 | 2/6 | 2/6 | 3/6 | 0/16 | 2/10 | 3/10 | 8/11 | 6/10 | 0/8 | 0/10 | 0/10 | 0/10 | 0/6 |
| Decreased appetiteGastrointestinal disorders | 0/4 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/16 | 1/10 | 2/10 | 5/11 | 6/10 | 1/8 | 0/10 | 3/10 | 6/10 | 0/6 |
| Injection site erythemaSurgical and medical procedures | 0/4 | 0/6 | 0/6 | 0/6 | 2/6 | 2/6 | 3/6 | 1/6 | 3/6 | 1/16 | 4/10 | 5/10 | 5/11 | 6/10 | 0/8 | 0/10 | 0/10 | 0/10 | 0/6 |
| Increased appetiteGastrointestinal disorders | 0/4 | 0/6 | 0/6 | 2/6 | 1/6 | 3/6 | 2/6 | 0/6 | 0/6 | 0/16 | 3/10 | 3/10 | 2/11 | 4/10 | 0/8 | 3/10 | 0/10 | 2/10 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 0/4 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/16 | 1/10 | 1/10 | 3/11 | 4/10 | 3/8 | 0/10 | 0/10 | 0/10 | 0/6 |
| Urinary tract infectionInfections and infestations | 0/4 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/16 | 0/10 | 0/10 | 0/11 | 0/10 | 0/8 | 0/10 | 3/10 | 1/10 | 2/6 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 0/4 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/16 | 0/10 | 0/10 | 0/11 | 0/10 | 0/8 | 0/10 | 0/10 | 0/10 | 2/6 |
| Blood uric acid increasedRenal and urinary disorders | 0/4 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/16 | 0/10 | 0/10 | 0/11 | 0/10 | 0/8 | 0/10 | 2/10 | 1/10 | 1/6 |
| Age, Continuous(Years) | Single-ascending Dose:Part1:DR10624 0.5mg | Single-ascending Dose:Part1:DR10624 1.5mg | Single-ascending Dose:Part1:DR10624 4.5mg | Single-ascending Dose:Part1:DR10624 12.5mg | Single-ascending Dose:Part1:DR10624 25mg | Single-ascending Dose:Part1:DR10624 50mg | Single-ascending Dose:Part1:DR10624 65mg | Single-ascending Dose:Part1:DR10624 90mg | Single-ascending Dose:Part1:DR10624 120mg | Single-ascending Dose:Part1:Placebo | Multiple-ascending Dose:Part2:DR10624 12.5mg | Multiple-ascending Dose:Part2:DR10624 25mg | Multiple-ascending Dose:Part2:DR10624 50mg | Multiple-ascending Dose:Part2:DR10624 75mg | Multiple-ascending Dose:Part2:Placebo | Single-ascending Dose:Part3:DR10624 25mg | Single-ascending Dose:Part3:DR10624 65mg | Single-ascending Dose:Part3:DR10624 90mg | Single-ascending Dose:Part3:Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 23.8 ± 2.36 | 27.3 ± 7.42 | 29.8 ± 10.17 | 26.5 ± 5.24 | 27.0 ± 13.48 | 28.8 ± 13.64 | 25.0 ± 5.90 | 32.0 ± 15.75 | 45.3 ± 10.39 | 34.1 ± 11.71 | 36.3 ± 10.64 | 37.8 ± 7.11 | 41.7 ± 8.30 | 42.8 ± 14.20 | 46.1 ± 11.89 | 34.4 ± 6.79 | 31.7 ± 5.38 | 37.3 ± 5.42 | 35.3 ± 8.31 | 34.9 ± 11.12 |
| Sex: Female, Male(Participants) | Single-ascending Dose:Part1:DR10624 0.5mg | Single-ascending Dose:Part1:DR10624 1.5mg | Single-ascending Dose:Part1:DR10624 4.5mg | Single-ascending Dose:Part1:DR10624 12.5mg | Single-ascending Dose:Part1:DR10624 25mg | Single-ascending Dose:Part1:DR10624 50mg | Single-ascending Dose:Part1:DR10624 65mg | Single-ascending Dose:Part1:DR10624 90mg | Single-ascending Dose:Part1:DR10624 120mg | Single-ascending Dose:Part1:Placebo | Multiple-ascending Dose:Part2:DR10624 12.5mg | Multiple-ascending Dose:Part2:DR10624 25mg | Multiple-ascending Dose:Part2:DR10624 50mg | Multiple-ascending Dose:Part2:DR10624 75mg | Multiple-ascending Dose:Part2:Placebo | Single-ascending Dose:Part3:DR10624 25mg | Single-ascending Dose:Part3:DR10624 65mg | Single-ascending Dose:Part3:DR10624 90mg | Single-ascending Dose:Part3:Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 3 | 1 | 1 | 3 | 6 | 5 | 3 | 4 | 10 | 3 | 4 | 7 | 4 | 4 | 3 | 4 | 4 | 6 | 78 |
| Male | 1 | 3 | 5 | 5 | 3 | 0 | 1 | 3 | 2 | 6 | 7 | 6 | 4 | 6 | 4 | 7 | 6 | 6 | 0 | 75 |
| Race (NIH/OMB)(Participants) | Single-ascending Dose:Part1:DR10624 0.5mg | Single-ascending Dose:Part1:DR10624 1.5mg | Single-ascending Dose:Part1:DR10624 4.5mg | Single-ascending Dose:Part1:DR10624 12.5mg | Single-ascending Dose:Part1:DR10624 25mg | Single-ascending Dose:Part1:DR10624 50mg | Single-ascending Dose:Part1:DR10624 65mg | Single-ascending Dose:Part1:DR10624 90mg | Single-ascending Dose:Part1:DR10624 120mg | Single-ascending Dose:Part1:Placebo | Multiple-ascending Dose:Part2:DR10624 12.5mg | Multiple-ascending Dose:Part2:DR10624 25mg | Multiple-ascending Dose:Part2:DR10624 50mg | Multiple-ascending Dose:Part2:DR10624 75mg | Multiple-ascending Dose:Part2:Placebo | Single-ascending Dose:Part3:DR10624 25mg | Single-ascending Dose:Part3:DR10624 65mg | Single-ascending Dose:Part3:DR10624 90mg | Single-ascending Dose:Part3:Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 1 | 0 | 2 | 1 | 10 | 10 | 10 | 6 | 46 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 4 | 1 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 13 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 3 | 5 | 4 | 3 | 6 | 6 | 3 | 5 | 6 | 10 | 4 | 6 | 7 | 6 | 4 | 0 | 0 | 0 | 0 | 78 |
| More than one race | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 7 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2022 to primary completion in Oct 2024, 27 months.
Results were first posted in Oct 2026, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: DR10624
Obesity, Metabolically Benign →
Zhejiang Doer Biologics Co., Ltd. →